US 12,434,076 B2
Low energy immune priming for treating cancer and metastasis
Chandan Guha, Scarsdale, NY (US); and Stephen Barry, Haddonfield, NJ (US)
Assigned to Montefiore Medical Center, Bronx, NY (US)
Filed by Montefiore Medical Center, Bronx, NY (US)
Filed on Jul. 15, 2024, as Appl. No. 18/773,093.
Application 18/773,093 is a continuation of application No. 16/865,761, filed on May 4, 2020, granted, now 12,070,628.
Application 16/865,761 is a continuation of application No. PCT/US2018/060138, filed on Nov. 9, 2018.
Claims priority of provisional application 62/596,715, filed on Dec. 8, 2017.
Claims priority of provisional application 62/584,064, filed on Nov. 9, 2017.
Prior Publication US 2025/0041631 A1, Feb. 6, 2025
Int. Cl. A61B 18/00 (2006.01); A61B 8/00 (2006.01); A61B 8/08 (2006.01); A61B 90/00 (2016.01); A61K 49/22 (2006.01); A61N 5/02 (2006.01); A61N 7/00 (2006.01); A61N 7/02 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01)
CPC A61N 7/00 (2013.01) [A61K 49/223 (2013.01); A61N 5/02 (2013.01); A61N 7/02 (2013.01); C07K 14/71 (2013.01); C07K 16/2878 (2013.01); A61B 8/4218 (2013.01); A61B 8/485 (2013.01); A61B 8/546 (2013.01); A61B 2018/00613 (2013.01); A61B 2018/00994 (2013.01); A61B 2090/374 (2016.02); A61N 2007/0004 (2013.01); A61N 2007/0052 (2013.01); A61N 2007/0078 (2013.01); A61N 2007/0082 (2013.01); C07K 2317/75 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for treating an individual having a cancer, the method comprising:
applying one or more ultrasound beams from an acoustic priming therapy system to the individual,
the system comprising:
a processor;
one or more ultrasound transducers coupled to the processor, wherein the one or more ultrasound transducers are configured to produce the one or more ultrasound beams such that a frequency waveform of the one or more ultrasound beams has a spatial peak temporal average acoustic output intensity (Ispta) of between 10 and 900 W/cm2; wherein the one or more ultrasound beams is a Low-Intensity Focused Ultrasound (LOFU) and induces a non-ablative stress in cells of a target treatment zone;
a probe coupled to the processor, wherein the probe is configured to monitor a patient;
and administering an antiandrogen to the individual.